The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients

Minerva Cardioangiologica

Volumn 56, Issue 5, 2008, Pages 467-476

  Farah, R ^a   Shurtz Swirski, R ^b  

^a Rebecca Sieff Government Hospital   (Israel)

^b WESTERN GALILEE HOSPITAL   (Israel)

Author keywords

Antioxidants; Hypertension; Inflammation; Lercanidipine; Oxidative stress

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; ASCORBIC ACID; C REACTIVE PROTEIN; CD11B ANTIGEN; CHOLESTEROL; GLUCOSE; LERCANIDIPINE; PHORBOL ESTER; SUPEROXIDE; UNCLASSIFIED DRUG; VASODIP;

ADULT; APOPTOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MALE; MEAN ARTERIAL PRESSURE; NEUTROPHIL; OXIDATIVE STRESS; PARAMETER; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED;

EID: 55749111967     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9.
2. Mosterd A, D'Agostino RB, Silbershatz H, Sytkowski PA, Kannel WB, Grobbee DE et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999;340:1221-7.
3. The 1993 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Blood pressure 1993;2: 86-100.
4. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspective. Hypertension 1995;25:155-61.
5. Smedly LA, Tonnesen MG, Sandhaus RA, Haslett C, Guthrie LA, Johnston RB Jr et al. Neutrophil-mediated injury to endothelial cells. J Clin Invest 1986;77:1233-43.
6. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-76.
7. Kristal B, Shurtz-Swirski R, Chezar J, Manaster J, Levy R, Shapiro G et al. Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens 1998;11:921-8.
8. Sela S, Shurtz-Swirski R, Farah R, Levy R, Shapiro G, Chezar J et al. A link between polymorphonuclear leukocyte intracellular calcium, plasma insulin, and essential hypertension. Am J Hypertens 2002;15:291-5.
9. Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G et al. The primed peripheral polymorphonuclear leukocyte - a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 2005;16:2431-8.
10. Shurtz-Swirski R, Sela S, Herskovits AT, Shasha SM, Shapiro G, Nasser L et al. Involvement of polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetes. Diabetes Care 2001;24:104-10.
11. Sela S, Shurtz-Swirski R, Awad J, Shapiro G, Nasser L, Shasha SM et al. The involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in cigarette smokers. IMAJ 2002;4:1015-9.
12. Tulenko TN, Sumner AE, Chen M, Huang Y, Laury-Kleintop L, Ferdinand FD. The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. Am Heart J 2001;141:S1-11.
13. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102:1503-10.
14. Hernandez RH, Armas-Hernandez MJ, Velasco M, Israili ZH, Armas-Padilla MC. Calcium antagonists and atherosclerosis protection in hypertension. Am J Ther 2003;10:409-14.
15. Napoli C, Salomone S, Godfraind T, Palinski W, Capuzzi DM, Palumbo G et al. 1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats. Stroke 1999;30: 1907-15.
16. Shurtz-Swirski R, Farah R, Sela S, Shapiro G, Klempef R, Snitkovski T et al. The effect of calcium channel blocker lercanidipine on low-grade inflammation parameters in essential hypertension patients. Harefuah 2006;145:895-9.
17. Klebanoff SJ, Clark RA. Iodination by human polymorphonuclear leukocytes: a re-evaluation. J Lab Clin Med 1977;89:675-86.
18. Babior BM, Kipnes RS, Curnutte JJ. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973;52:741-4.
19. Yoon JW, Pahl MV, Vaziri ND. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int 2007;71:167-72.
20. Kuypers FA, Lewis RA, Hua M, Schott MA, Discher D, Ernst JD et al. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled Annexin V. Blood 1996;87:1179-87.
21. Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O'Shea S, Owen WF Jr et al. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003;18:1167-73.
22. Pifer TB, McCullough KP, Port FK, Goodkin DA, Maroni BJ, Held PJ et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002;62:2238-45.
23. Erlinger TP, Tarver-Carr ME, Powe NR, Appel LJ, Coresh J, Eberhardt MS et al. Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. Am J Kidney Dis 2003;42:256-63.
24. Sato K, Dohy Y, Kojima M, Miygawa K, Takase H, Katada E et al. Effect of ascorbic acid on ambulatory blood pressure in elderly patients with refractory hypertension. Arzneimittelforschung 2006;56:535-40.
25. Kunitomo M. [Oxidative stress and atherosclerosis]. Yakugaku Zasshi 2007;127:1997-2014.
26. Riccioni G, Bucciarelli T, Mancini B, Corradi F, Di Ilio C, Mattei PA et al. Antioxidant vitamin supplementation in cardiovascular diseases. Ann Clin Lab Sci 2007;37:89-95.
27. Rodrigo R, Prat H, Passalacqua W, Araya J, Bächler JP. Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension. Clin Sci (Lond) 2008;114:625-34.
28. Tsirpanlis G, Bagos P, Ioannou D, Bleta A, Marinou I, Lagouranis A et al. Serum albumin: a late- reacting negative acute-phase protein in clinically evident inflammation in dialysis patients. Nephrol Dial Transplant 2005;20:658-9.
29. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
30. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
31. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144:537-47.
32. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J. Benidipine, a long-acting calcium channel blocker, inhibits oxidative stress in polymorphonuclear cells in patients with essential hypertension. Hypertens Res 2005;28:107-12.
33. Tomlinson B, Benzie IF. Antioxidant effect of Lercanidipine. Hypertension 2003;42:10-1.
34. Bellosta S, Bernini F. Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr Atheroscler Rep 2000;2:76-81.